Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.

In a recent Phase II clinical study of 40 patients with aggressive corneal neovascularization and nonresponsive to conventional therapy, GS-101 was reported to induce highly significant regression of corneal neovascularization compared with the placebo group, where corneal neovascularization progressed in all patients [20] .

also in 132,142 other papers